- Home
- CELU vs CLNN Comparison
CELU vs CLNN Comparison
Compare CELU & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- CLNN
- Stock Information
- Founded
- CELU 2016
- CLNN 2012
- Country
- CELU United States
- CLNN United States
- Employees
- CELU N/A
- CLNN N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- CLNN Health Care
- Exchange
- CELU Nasdaq
- CLNN Nasdaq
- Market Cap
- CELU 49.9M
- CLNN 43.0M
- IPO Year
- CELU N/A
- CLNN N/A
- Fundamental
- Price
- CELU $2.24
- CLNN $4.34
- Analyst Decision
- CELU
- CLNN Strong Buy
- Analyst Count
- CELU 0
- CLNN 4
- Target Price
- CELU N/A
- CLNN $55.25
- AVG Volume (30 Days)
- CELU 231.0K
- CLNN 121.1K
- Earning Date
- CELU 11-07-2024
- CLNN 11-13-2024
- Dividend Yield
- CELU N/A
- CLNN N/A
- EPS Growth
- CELU N/A
- CLNN N/A
- EPS
- CELU N/A
- CLNN N/A
- Revenue
- CELU $48,200,000.00
- CLNN $421,000.00
- Revenue This Year
- CELU N/A
- CLNN N/A
- Revenue Next Year
- CELU $233.89
- CLNN N/A
- P/E Ratio
- CELU N/A
- CLNN N/A
- Revenue Growth
- CELU 225.94
- CLNN N/A
- 52 Week Low
- CELU $1.30
- CLNN $3.82
- 52 Week High
- CELU $7.97
- CLNN $12.00
- Technical
- Relative Strength Index (RSI)
- CELU 46.60
- CLNN 44.40
- Support Level
- CELU $2.17
- CLNN $4.22
- Resistance Level
- CELU $2.43
- CLNN $5.47
- Average True Range (ATR)
- CELU 0.26
- CLNN 0.45
- MACD
- CELU -0.01
- CLNN 0.06
- Stochastic Oscillator
- CELU 54.02
- CLNN 30.57
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).